KRAS driven lung adenocarcinoma depends on ERBB signaling

Several clinical trials using first generation EGFR Tyrosine Kinase Inhibitors (TKIs, erlotinib and gefitinib) in patients suffering of lung adenocarcinoma (AC) harboring activating mutations in the KRAS gene have shown disappointing results. Therefore, it has become a dogma that KRAS driven lung AC do not respond to TKIs and targeting EGFR is not considered a therapeutic option to treat patients suffering of KRAS mutated lung AC. In agreement we that, we have sho